GMP BIO

GMP BIO Co., LTD., established in July 2000, has developed based on the foundation of natural drug new drug development. Currently, to develop one of the next-generation growth drivers—cellular therapeutics—the company is focusing on treating degenerative brain diseases. The drugs currently undergoing clinical trials include a natural product-based dementia treatment, an antidepressant, and an acute bronchitis treatment (technical name: chronic pneumonia treatment) that has been transferred through Hankil Pharmaceutical's technology transfer with a Phase 3 clinical trial license.